Fluorodopa

In this article, the topic of Fluorodopa will be addressed from a broad and timeless perspective, in order to offer readers an exhaustive and complete analysis of this topic of general interest. Different facets and approaches related to Fluorodopa will be explored, with the aim of providing a comprehensive vision that allows it to be understood from different angles. Through this article, we aim to offer readers an enriching and detailed vision of Fluorodopa, allowing them to expand their knowledge and understanding of the subject.

Not to be confused with Florbetapir (18F).

Fluorodopa
Clinical data
Trade namesFluorodopa F18
Other names6-fluoro-L-DOPA, FDOPA
License data
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
  • (2S)-2-amino-3-(2-(18F)fluoranyl-4,5-dihydroxyphenyl)propanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC9H10FNO4
Molar mass214.18 g·mol−1
3D model (JSmol)
  • C1=C(C(=CC(=C1O)O)F)CC(C(=O)O)N
  • InChI=1S/C9H10FNO4/c10-5-3-8(13)7(12)2-4(5)1-6(11)9(14)15/h2-3,6,12-13H,1,11H2,(H,14,15)/t6-/m0/s1/i10-1
  • Key:PAXWQORCRCBOCU-RPDRGXCHSA-N

Fluorodopa, also known as FDOPA, is a fluorinated form of L-DOPA primarily synthesized as its fluorine-18 isotopologue for use as a radiotracer in positron emission tomography (PET).[1]

The most common side effects are injection site pain.[2]

Medical uses

Fluorodopa is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adults with suspected Parkinsonian syndromes (PS).[2]

History

In October 2019, Fluorodopa was approved in the United States for the visual detection of certain nerve cells in adult patients with suspected Parkinsonian Syndromes (PS).[3][4]

The U.S. Food and Drug Administration (FDA) approved Fluorodopa F 18 based on evidence from one clinical trial of 56 patients with suspected PS.[3] The trial was conducted at one clinical site in the United States.[3]

References

  1. ^ Deng WP, Wong KA, Kirk KL (June 2002). "Convenient syntheses of 2-, 5- and 6-fluoro- and 2,6-difluoro-L-DOPA". Tetrahedron: Asymmetry. 13 (11): 1135–1140. doi:10.1016/S0957-4166(02)00321-X.
  2. ^ a b "Fluorodopa F18 injection". DailyMed. 12 October 2019. Retrieved 26 April 2020.
  3. ^ a b c "Drug Trials Snapshots: Fluorodopa F 18". U.S. Food and Drug Administration (FDA). 27 November 2019. Archived from the original on 27 November 2019. Retrieved 27 November 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ "Drug Approval Package: Fluorodopa F18". U.S. Food and Drug Administration (FDA). 20 November 2019. Archived from the original on 27 November 2019. Retrieved 26 November 2019. Public Domain This article incorporates text from this source, which is in the public domain.